SAN
DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati
Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage
biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will
depart the company on September 8,
2023, to pursue an external opportunity. Aaron Ondrey, senior vice president, financial
planning and analysis (FP&A), Mirati Therapeutics, will assume
the role of interim CFO. Ms. Stelzer will remain as a consultant to
the company through October 2023.
"On behalf of the Board and the Company, we thank Laurie for her
leadership and the contributions made during her tenure," said
Charles M. Baum, M.D., Ph.D.,
interim CEO, president and founder, Mirati Therapeutics.
"It has been a privilege to serve as CFO of Mirati and I am
grateful for the opportunity and the experience to work alongside a
team committed to positively impacting the lives of patients," said
Laurie Stelzer, chief financial
officer, Mirati Therapeutics. "The caliber, commitment and
expertise of the Mirati team will continue to inspire me. I look
forward to the Company's future success."
Mr. Ondrey joined Mirati as senior vice president, FP&A, in
July of 2022, bringing over 20 years of experience in financial
management, strategic planning, capital allocation and mergers and
acquisitions. Previously, he held senior leadership roles at Arena
Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. and Regeneron
Pharmaceuticals, Inc.
Mirati recently completed an upsized public offering, further
extending the Company's cash runway ahead of several upcoming
milestones.
About Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a commercial stage biotechnology
company whose mission is to discover, design and deliver
breakthrough therapies to transform the lives of patients with
cancer and their loved ones. The company is relentlessly focused on
bringing forward therapies that address areas of high unmet need,
including lung cancer, and advancing a pipeline of novel
therapeutics targeting the genetic and immunological drivers of
cancer. Unified for patients, Mirati's vision is to unlock the
science behind the promise of a life beyond cancer.
For more information about Mirati, visit us
at Mirati.com or follow us
on Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release includes forward-looking statements regarding
Mirati's business, financial guidance and the therapeutic and
commercial potential of KRAZATI® (adagrasib),
MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1
inhibitor), and MRTX1133 (selective KRASG12D inhibitor), Mirati's
technologies and Mirati's other products in development. Any
statement describing Mirati's goals, expectations, intentions or
beliefs, financial or other projections, is a forward-looking
statement and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties including
those inherent in the process of discovering, developing and
commercializing medicines that are safe and effective for use as
human therapeutics, and in the endeavor of building a business
around such medicines.
Mirati's forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its
results to differ materially from those expressed or implied by
such forward-looking statements. Although Mirati's forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Mirati. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning
Mirati's programs are described in additional detail in Mirati's
annual report on Form 10-K, and most recent Form 10-Q, which are on
file with the Securities and Exchange Commission and available at
the SEC's Internet site (https://www.sec.gov/). These
forward-looking statements are made as of the date of this press
release, and Mirati assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-departure-of-chief-financial-officer-laurie-stelzer-301908485.html
SOURCE Mirati Therapeutics, Inc.